<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90748">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01935453</url>
  </required_header>
  <id_info>
    <org_study_id>OrienGene-01</org_study_id>
    <nct_id>NCT01935453</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer</brief_title>
  <official_title>A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrienGene Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>START Shanghai Company Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Bozhiyin T&amp;S Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OrienGene Biotechnology Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds
      of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Exploring the MTD of OrienX010 according to DLT,which defined as the serious degree of adverse events relates to the medicine not less than grade 3 of CTCAE v4.03</measure>
    <time_frame>28 days after the last administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Using RECIST 1.1 to evaluate the preliminary efficacy of OrienX010</measure>
    <time_frame>28 days after the last administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Melanoma</condition>
  <condition>Liver Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Recombinant HSV-1 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant hGM-CSF Herpes Simplex Virus Injection</intervention_name>
    <arm_group_label>Recombinant HSV-1 Injection</arm_group_label>
    <other_name>OrienX010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients in advanced stage of malignant tumor diagnosticated by pathologic  and
             cytological analysis.

          -  lack of routine effective treatment,failure of routine treatment or relapse

          -  age of 18-70,ECOG 0-2 and estimated survival is above 3 months

          -  had an interval of above 4 weeks since exposure to chemotherapy or radiotherapy and
             above 6 weeks since exposure to nitrosoureas or mitomycin C.

        Exclusion Criteria:

          -  Serious internal diseases

          -  uncontrolled primary and metastatic brain tumor

          -  sizes of tumor does not meet the requirement of injection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Ren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Shijitan Hospital,CMU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital,CMU</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinna Zhou</last_name>
      <phone>86-10-63926220</phone>
    </contact>
    <investigator>
      <last_name>Jun Ren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, MD</last_name>
      <email>fudanlijin@163.com</email>
    </contact>
    <investigator>
      <last_name>Jin Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 30, 2013</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
